Quetiapine

also known as Seroquel · quetiapine fumarate · quetiapine XR · Seroquel XR · Seroquel SR · FK949E · Seroquel SRTM · Quetiapine Fumarate Extended-Release · +14 more

Small molecule

Developed for: schizophrenia · major depressive disorder · bipolar disorder · schizoaffective disorder · bipolar depression · generalized anxiety disorder · depressive disorder · delirium
+46 more
· manic bipolar affective disorder · post-traumatic stress disorder · psychotic disorder · alcohol dependence · bipolar I disorder · insomnia · social phobia · substance-related disorder · Alzheimer disease · anxiety · obsessive-compulsive disorder · bipolar II disorder · dementia · postpartum depression · alcohol abuse · anorexia nervosa · anxiety disorder · attention deficit-hyperactivity disorder · borderline personality disorder · cannabis dependence · fibromyalgia · mood disorder · bowel dysfunction · chronic kidney disease · cocaine dependence · cognitive impairment with or without cerebellar ataxia · drug-induced dyskinesia · dysthymic disorder · methamphetamine dependence · multiple sclerosis · neurotic disorder · obstructive sleep apnea syndrome · panic disorder · Parkinson disease · schizophreniform disorder · sleep disorder, initiating and maintaining sleep · specific phobia · substance abuse · substance dependence · traumatic brain injury · vascular dementia · alcohol-related disorders · COVID-19 · drug-induced akathisia · Lewy body dementia · viral pneumonia
Investigated by: AstraZeneca · Astellas Pharma Inc · Massachusetts General Hospital · National Institute of Mental Health (NIMH) · National Institute on Drug Abuse (NIDA) · University of Cincinnati
+186 more
· H. Lundbeck A/S · Shanghai Mental Health Center · Duke University · Janssen Research & Development, LLC · Janssen, LP · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · New York State Psychiatric Institute · Shanghai Jiao Tong University School of Medicine · US Department of Veterans Affairs · University of California, San Diego · University of Sao Paulo · Centre for Addiction and Mental Health · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Copenhagen Trial Unit, Center for Clinical Intervention Research · Dr Alexander McIntyre Inc. · Dr. Inge Winter · Emory University · Hannover Medical School · Hospital de Clinicas de Porto Alegre · Indiana University · Inje University · National Alliance for Research on Schizophrenia and Depression · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Region Capital Denmark · Seattle Institute for Biomedical and Clinical Research · Seoul National University Bundang Hospital · Technical University of Munich · The University of Hong Kong · The University of Texas Health Science Center at San Antonio · University of Minnesota · University of Montreal · University of Münster · University of Pennsylvania · University of South Florida · Weill Medical College of Cornell University · AP Moeller Foundation · Abbott · Agency for Healthcare Research and Quality (AHRQ) · Ain Shams University · Air Force Military Medical University, China · Albert Einstein College of Medicine · Alexandria University · Allocated inheritance from Elizabeth Stevn and Niels Rindom, Denmark · Anne Katrine Pagsberg · Arthur P. Noyes Research Foundation · Assiut University · Augusta University · Avon and Wiltshire Mental Health Partnership NHS Trust · BC Women's Hospital & Health Centre · Bayside Health · Beth Israel Medical Center · Biomedical Research Institute of New Mexico · Birte Glenthoj · Boston Medical Center · Cambridge Health Alliance · Canadian Psychiatric Research Foundation · Central Institute of Mental Health, Mannheim · Centro de Investigación Biomédica en Red de Salud Mental · Chiang Mai University · Copenhagen Hospital Corporation · Copenhagen University Hospital, Hvidovre · Corporation de Recherche en Neuropsycho Pharmacologie de Quebec · Creighton University · Dalian Seventh People's Hospital · Danish Center for Sleep Medicine · Dartmouth-Hitchcock Medical Center · Dr Rabia Arshad · Eli Lilly and Company · Ewha Womans University · Federal Stare Budgetary Scientific Institution, Mental Health Research Center · Federal State Budgetary Institution V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Saint-Petersburg, Russia · Federal University of Rio Grande do Sul · First Affiliated Hospital of Jinan University · First Affiliated Hospital of Zhejiang University · all 192 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (5)	US (FDA)	SEROQUEL	—	2004-01-12 – 2013-04-30	fda.gov ↗
Label expansion	US (FDA)	SEROQUEL XR	—	2008-10-08	fda.gov ↗
Approved	US (FDA)	SEROQUEL	—	1997-09-26	fda.gov ↗

Trials 244 · started per year

today

US approved 1997

19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT04280965	Feb 2019 → Apr 2022	post-traumatic stress disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 0	NCT00567866	Jan 2008 → Sep 2009	methamphetamine dependence	University of Arkansas	Terminated	No outcome recorded
Phase 0	NCT00606541	Jan 2008 → Dec 2011	social phobia	Duke University	Terminated	No outcome recorded
Phase 119 trials
Phase 1	NCT05240261	May 2022 → May 2024	chronic kidney disease	Assiut University	Unknown	No outcome recorded
Phase 1	NCT04950868	Mar 2022 → Jun 2025 overdue	postpartum depression	Verinder Sharma	Active not recruiting	No outcome recorded
Phase 1	NCT03872596	Mar → Oct 2019	bipolar disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT02901587	Sep 2016 → Apr 2018	schizoaffective disorder, schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded
Phase 1	NCT02131545	Jun 2014 → Jul 2016	delirium, dementia	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02087579	Feb → Oct 2014	bipolar disorder, depressive disorder, schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02051387	Jan 2013 → Aug 2017	schizophrenia	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 1	NCT01871701	Nov 2012 → May 2014	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT01919008	Mar → Jun 2012	major depressive disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01607762	Feb → Apr 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01908296	Jul → Aug 2011	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01924520	Nov 2010 → May 2011	major depressive disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01903200	Feb 2010 → Sep 2011	major depressive disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01871987	Jun → Aug 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00919607	Jun 2009 → Mar 2010	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01871974	May 2009 → Mar 2010	major depressive disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00702676	Jul → Aug 2008	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00087750	Oct 2003 → ?	substance-related disorder	National Institute on Drug Abuse (NIDA)	Unknown	No outcome recorded
Phase 1	NCT00255879	Jan 1999 → Aug 2004	drug-induced dyskinesia	University of California, San Diego	Completed	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT02056171	Mar 2015 → Dec 2016	delirium	Weill Medical College of Cornell University	Terminated	No outcome recorded
Phase 1/2	NCT02087631	Dec 2014 → Jul 2019	multiple sclerosis	University of Calgary	Completed	No outcome recorded
Phase 1/2	NCT02650102	Jan 2013 → Dec 2016	schizophrenia	Shanxi Medical University	Unknown	No outcome recorded
Phase 220 trials
Phase 2	NCT07152184	Oct 2026 → Feb 2032 expected	schizophrenia	University Hospital, Strasbourg, France	Not yet recruiting	No outcome recorded
Phase 2	NCT05793632	Mar → Apr 2023	delirium	Ain Shams University	Completed	No outcome recorded
Phase 2	NCT05303935	May 2022 → Apr 2023	obstructive sleep apnea syndrome	Flinders University	Completed	No outcome recorded
Phase 2	NCT02462473	May 2015 → Jan 2016	schizoaffective disorder, schizophrenia	Janssen Research & Development, LLC	Terminated	No outcome recorded
Phase 2	NCT01697709	Oct 2012 → Apr 2017	cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT01189318	Mar 2012 → Feb 2014	major depressive disorder	Ewha Womans University	Withdrawn	No outcome recorded
Phase 2	NCT01725282	Dec 2011 → Aug 2013	major depressive disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT00954681	Aug 2009 → Aug 2010	cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00872716	Apr 2009 → Mar 2011	specific phobia	University Hospital Muenster	Completed	No outcome recorded
Phase 2	NCT00743366	Aug 2008 → Mar 2009	—	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00674765	Jan 2008 → Jan 2013	alcohol dependence	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT00622245	Jan 2008 → Jan 2009	bipolar depression	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 2	NCT00498628	Dec 2007 → Aug 2009	alcohol abuse, alcohol dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 2	NCT00681668	Aug 2007 → Oct 2008	postpartum depression	AstraZeneca	Terminated	No outcome recorded
Phase 2	NCT00584688	Feb 2007 → Jun 2009	anorexia nervosa	University of South Florida	Terminated	No outcome recorded
Phase 2	NCT00733668	Mar 2006 → Nov 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00254787	Jun 2005 → Jan 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00254748	Jun 2004 → Jun 2007	borderline personality disorder	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00550147	Feb 2004 → Nov 2005	attention deficit-hyperactivity disorder	Indiana University	Completed	No outcome recorded
Phase 2	NCT00318539	Dec 2003 → Aug 2006	obsessive-compulsive disorder	AstraZeneca	Completed	No outcome recorded

Phase 2/36 trials
Phase 2/3	NCT06062953	Sep 2023 → Feb 2029 expected	insomnia, psychiatric disorder	Lone Baandrup	Recruiting	No outcome recorded
Phase 2/3	NCT03572257	Apr 2019 → Feb 2020	delirium	Medical College of Wisconsin	Withdrawn	No outcome recorded
Phase 2/3	NCT01725308	Feb 2012 → Aug 2015	bipolar disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2/3	NCT00411463	Dec 2006 → Sep 2010	bipolar II disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 2/3	NCT00297947	Dec 2004 → Oct 2014	schizoaffective disorder, schizophrenia	Manhattan Psychiatric Center	Completed	No outcome recorded
Phase 2/3	NCT00215254	Mar 2004 → Feb 2006	social phobia	Duke University	Completed	No outcome recorded
Phase 391 trials
Phase 3	NCT05603104	Apr 2025 → Jun 2028 expected	bipolar depression, major depressive disorder, schizophrenia	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT05973786	Feb 2025 → Jun 2028 expected	bipolar depression	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT06333990	Jul 2024 → Jun 2028 expected	traumatic brain injury	Foundation for Advancing Veterans' Health Research	Recruiting	No outcome recorded
Phase 3	NCT05690698	Apr → Jul 2023	delirium	Alexandria University	Completed	No outcome recorded
Phase 3	NCT03739476	Feb 2019 → Apr 2020	delirium	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León	Terminated	No outcome recorded
Phase 3	NCT02362412	Feb 2015 → Feb 2016	bipolar depression	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT01858948	Jul 2013 → Apr 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT01810380	Mar 2013 → Dec 2014	schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded
Phase 3	NCT01811459	Feb 2013 → Sep 2016	delirium	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 3	NCT01765829	Nov 2012 → Nov 2015	psychotic disorder	Fundación Pública Andaluza Progreso y Salud	Unknown	No outcome recorded
Phase 3	NCT01737268	Oct 2012 → Jun 2016	bipolar disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT01256177	Dec 2010 → Nov 2012	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01197846	Sep 2010 → Feb 2012	bipolar disorder	Centro de Investigación Biomédica en Red de Salud Mental	Completed	No outcome recorded
Phase 3	NCT01071135	Sep 2009 → Aug 2010	schizophrenia	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT00953108	Sep 2009 → Feb 2012	major depressive disorder	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 3	NCT00954603	Jun 2009 → Apr 2011	delirium	Chiang Mai University	Terminated	No outcome recorded
Phase 3	NCT00857584	May 2009 → Feb 2011	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00882518	Apr 2009 → Jul 2010	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00883493	Apr 2009 → Mar 2011	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00879307	Mar 2009 → Sep 2011	bipolar disorder	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 3	NCT00852631	Feb 2009 → May 2010	schizophrenia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00811473	Jan 2009 → Nov 2010	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01672554	Dec 2008 → Apr 2012	anxiety, schizophrenia	Corporation de Recherche en Neuropsycho Pharmacologie de Quebec	Unknown	No outcome recorded
Phase 3	NCT02142556	Nov 2008 → Mar 2012	schizophrenia	Tri-Service General Hospital (TSGH)	Completed	No outcome recorded
Phase 3	NCT00782405	Oct 2008 → Apr 2011	—	Technical University of Munich	Completed	No outcome recorded
Phase 3	NCT00751504	Sep 2008 → Jul 2012	psychotic disorder	Ruhr University of Bochum	Completed	No outcome recorded
Phase 3	NCT00660595	Sep → Dec 2008	schizophrenia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00868374	Jun 2008 → Oct 2011	generalized anxiety disorder, major depressive disorder	Keming Gao	Terminated	No outcome recorded
Phase 3	NCT00671853	Apr 2008 → Mar 2011	anxiety, bipolar disorder, substance-related disorder	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 3	NCT00640601	Mar 2008 → Jul 2010	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00640562	Feb 2008 → Feb 2010	depressive disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00600756	Jan 2008 → Oct 2009	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00534599	Aug 2007 → Sep 2008	anxiety, neurotic disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00434876	Aug 2007 → Nov 2009	alcohol dependence, sleep disorder, initiating and maintaining sleep	Subhajit Chakravorty	Completed	No outcome recorded
Phase 3	NCT00457899	Jul → Sep 2007	schizoaffective disorder, schizophrenia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00486798	May → Aug 2007	bipolar disorder, schizophrenia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00422123	Jan → Jul 2007	manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00347425	Dec 2006 → Feb 2008	schizophrenia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00422214	Dec 2006 → Jun 2007	bipolar depression, manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00388973	Sep 2006 → Dec 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00389064	Sep 2006 → Apr 2008	generalized anxiety disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00302770	Jun → Dec 2006	social phobia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00351169	May 2006 → Jun 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00322595	May 2006 → May 2007	generalized anxiety disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00351910	May 2006 → Apr 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00334126	Apr 2006 → Sep 2007	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00326105	Apr 2006 → Jul 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00320268	Apr 2006 → May 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00326144	Apr 2006 → May 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00329446	Apr 2006 → Sep 2007	generalized anxiety disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00321490	Apr 2006 → May 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00329264	Apr 2006 → Aug 2007	generalized anxiety disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00314210	Mar 2006 → Aug 2007	anxiety disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00114686	Jan 2006 → Apr 2007	alcohol dependence, bipolar I disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00278941	Dec 2005 → Aug 2007	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00232414	Oct 2005 → Dec 2007	bipolar I disorder	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT00206141	Aug 2005 → May 2007	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00174603	Aug 2005 → Jan 2007	major depressive disorder	Rush University Medical Center	Terminated	No outcome recorded
Phase 3	NCT00448578	Aug 2005 → Jun 2006	manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00119652	May 2005 → May 2007	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00122070	May 2005 → Sep 2007	borderline personality disorder	University of Medicine and Dentistry of New Jersey	Completed	No outcome recorded
Phase 3	NCT00228462	Mar 2005 → Apr 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00314184	Mar 2005 → Jul 2007	bipolar disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00306540	Dec 2004 → Sep 2007	post-traumatic stress disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00206115	Nov 2004 → Dec 2005	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00206128	Nov 2004 → Feb 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00234377	Nov 2004 → May 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00097032	Oct 2004 → May 2005	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00254813	Oct 2004 → Sep 2005	psychotic disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00090324	Sep 2004 → Jun 2007	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00227305	Aug 2004 → Dec 2007	bipolar I disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00304473	Aug 2004 → Apr 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00090311	Jul 2004 → Jul 2006	bipolar disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00252226	Jun 2004 → Dec 2007	bipolar disorder	Mood Disorders Center of Ottawa	Completed	No outcome recorded
Phase 3	NCT00083954	Jun 2004 → Aug 2005	bipolar disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00085891	Jun 2004 → Sep 2005	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00107731	Apr 2004 → Oct 2006	bipolar I disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00081380	Mar 2004 → Sep 2006	bipolar disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00277667	Feb 2004 → Dec 2007	bipolar disorder	Lindner Center of HOPE	Completed	No outcome recorded
Phase 3	NCT00161018	Nov 2003 → Nov 2004	schizophrenia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 3	NCT00328978	Oct 2003 → Sep 2005	schizoaffective disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00449397	Jul 2003 → Jan 2006	psychotic disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00221468	Jun 2003 → Apr 2006	mood disorder	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT00124059	Mar 2003 → Sep 2005	alcohol dependence	University of Pennsylvania	Completed	No outcome recorded
Phase 3	NCT00060489	Sep 2002 → Sep 2003	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00621647	Sep 2002 → Nov 2003	Alzheimer disease, vascular dementia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00254735	Apr 2002 → Mar 2006	obsessive-compulsive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00254774	Jan 2002 → Mar 2006	bipolar disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00305422	Nov 2001 → Jan 2003	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00159770	Nov 2001 → Sep 2004	schizoaffective disorder, schizophrenia	Viatris Inc.	Completed	No outcome recorded

Phase 476 trials
Phase 4	NCT06433635	Oct 2024 → Feb 2030 expected	bipolar I disorder, depressive disorder	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT04446234	May 2021 → Dec 2022	schizophrenia	Shanghai Mental Health Center	Unknown	No outcome recorded
Phase 4	NCT02845453	Jan 2017 → Apr 2021	bipolar disorder, substance-related disorder	Boston Medical Center	Completed	No outcome recorded
Phase 4	NCT03004521	Nov 2016 → Apr 2021	mood disorder	King's College London	Unknown	No outcome recorded
Phase 4	NCT02307396	Feb 2015 → Jun 2016	schizoaffective disorder, schizophrenia	Technical University of Munich	Completed	No outcome recorded
Phase 4	NCT01893229	Sep 2013 → Dec 2015	bipolar disorder	Guiyun Xu	Unknown	No outcome recorded
Phase 4	NCT01938859	Jun 2012 → Dec 2017	bipolar disorder	Shanghai Mental Health Center	Unknown	No outcome recorded
Phase 4	NCT01357967	May 2011 → Dec 2012	major depressive disorder	Inje University	Unknown	No outcome recorded
Phase 4	NCT01254721	Dec 2010 → Oct 2012	manic bipolar affective disorder	AstraZeneca	Terminated	No outcome recorded
Phase 4	NCT01250847	Nov 2010 → Oct 2011	schizophrenia	Severance Hospital	Unknown	No outcome recorded
Phase 4	NCT01213121	Sep 2010 → Oct 2014	bipolar depression	Seoul National University Bundang Hospital	Unknown	No outcome recorded
Phase 4	NCT01331304	Sep 2010 → Apr 2013	bipolar disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01133821	Aug 2010 → Oct 2015	bipolar II disorder, depressive disorder	Holly Swartz	Completed	No outcome recorded
Phase 4	NCT01128114	Jun 2010 → Mar 2011	manic bipolar affective disorder	AstraZeneca	Terminated	No outcome recorded
Phase 4	NCT01119014	May 2010 → Jul 2015	psychotic disorder	Anne Katrine Pagsberg	Completed	No outcome recorded
Phase 4	NCT01164059	Feb 2010 → Aug 2013	schizophrenia	University of Bremen	Completed	No outcome recorded
Phase 4	NCT00746421	Jan 2010 → Apr 2012	bipolar disorder, cognitive impairment with or without cerebellar ataxia	Emory University	Terminated	No outcome recorded
Phase 4	NCT00986167	Oct 2009 → Oct 2010	schizophrenia	Bayside Health	Unknown	No outcome recorded
Phase 4	NCT00954122	Sep 2009 → Mar 2010	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00951483	Jul 2009 → Oct 2011	anxiety, depressive disorder	Loyola University	Completed	No outcome recorded
Phase 4	NCT00892463	May 2009 → Dec 2010	major depressive disorder	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT01016145	Apr 2009 → Jun 2010	psychotic disorder	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT00982345	Mar 2009 → Mar 2012	major depressive disorder	Indiana University	Completed	No outcome recorded
Phase 4	NCT00837343	Dec 2008 → Oct 2010	bipolar disorder	Guangzhou Mental Hospital	Unknown	No outcome recorded
Phase 4	NCT00817648	Dec 2008 → May 2010	schizophrenia	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 4	NCT00779506	Nov 2008 → Jul 2009	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00766350	Nov 2008 → Mar 2010	fibromyalgia	University of Granada	Completed	No outcome recorded
Phase 4	NCT00955474	Sep 2008 → Jan 2013	major depressive disorder	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 4	NCT01244711	Sep 2008 → Sep 2011	generalized anxiety disorder, major depressive disorder	Weill Medical College of Cornell University	Terminated	No outcome recorded
Phase 4	NCT01200901	Sep 2008 → Sep 2012	depressive disorder	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00186043	Aug 2008 → Aug 2011	bipolar II disorder	Stanford University	Completed	No outcome recorded
Phase 4	NCT00838032	Aug 2008 → May 2010	schizophrenia	Sichuan University	Unknown	No outcome recorded
Phase 4	NCT00521365	May 2008 → Aug 2009	manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00253266	Apr 2008 → Apr 2014	depressive disorder	Max-Planck-Institute of Psychiatry	Completed	No outcome recorded
Phase 4	NCT00983320	Apr 2008 → Oct 2011	fibromyalgia	University of Sherbrooke	Completed	No outcome recorded
Phase 4	NCT00672490	Apr 2008 → Jul 2009	manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01000402	Feb 2008 → Oct 2012	attention deficit-hyperactivity disorder, bipolar disorder	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
Phase 4	NCT00668265	Jan 2008 → Aug 2011	generalized anxiety disorder, opiate dependence	Beth Israel Medical Center	Terminated	No outcome recorded
Phase 4	NCT00511277	Aug 2007 → Oct 2010	schizophrenia	Institute of Application-oriented Research and Clinical Trials GmbH	Completed	No outcome recorded
Phase 4	NCT00498004	Aug 2007 → Sep 2008	schizophrenia	Inje University	Terminated	No outcome recorded
Phase 4	NCT00723970	Jun 2007 → May 2009	insomnia, major depressive disorder	McMaster University	Completed	No outcome recorded
Phase 4	NCT00466609	May 2007 → Mar 2010	obsessive-compulsive disorder	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT00370500	Apr 2007 → Jul 2008	schizophrenia	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 4	NCT00675896	Apr 2007 → Jun 2011	major depressive disorder	Dr Alexander McIntyre Inc.	Completed	No outcome recorded
Phase 4	NCT00797927	Jan 2007 → Mar 2009	schizophrenia	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT00428350	Dec 2006 → Sep 2007	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00407199	Dec 2006 → Sep 2007	social phobia	University of Minnesota	Completed	No outcome recorded
Phase 4	NCT03207438	Apr 2006 → Jul 2007	major depressive disorder	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00292370	Jan 2006 → Dec 2008	combat disorder, post-traumatic stress disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT00854919	Jan 2006 → Dec 2007	—	Osaka City University	Completed	No outcome recorded
Phase 4	NCT00564564	Jan 2006 → Dec 2007	obsessive-compulsive disorder	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT00255515	Sep 2005 → Dec 2007	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00139074	Jul 2005 → Jun 2006	bipolar disorder	AstraZeneca	Terminated	No outcome recorded
Phase 4	NCT00181883	Feb 2005 → Apr 2009	manic bipolar affective disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00090012	Jul 2004 → Mar 2006	schizoaffective disorder, schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00214578	Apr 2004 → Oct 2005	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00156715	Mar 2004 → Sep 2006	alcohol abuse, schizoaffective disorder, schizophrenia	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 4	NCT00113295	Feb 2004 → Feb 2007	generalized anxiety disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00229645	Nov 2003 → Apr 2005	major depressive disorder	Dr Alexander McIntyre Inc.	Completed	No outcome recorded
Phase 4	NCT00208143	Nov 2003 → Dec 2005	schizoaffective disorder, schizophrenia, substance abuse, substance dependence	Creighton University	Completed	No outcome recorded
Phase 4	NCT00182442	Oct 2003 → Mar 2006	schizophrenia	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT00232336	Oct 2003 → Jan 2006	substance-related disorder	Seattle Institute for Biomedical and Clinical Research	Completed	No outcome recorded
Phase 4	NCT00206102	Sep 2003 → Oct 2008	schizoaffective disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00208819	Sep 2003 → Jul 2007	Alzheimer disease	Emory University	Completed	No outcome recorded
Phase 4	NCT00334035	Aug 2003 → Jun 2007	schizophrenia	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00237393	Aug 2003 → Dec 2007	post-traumatic stress disorder	Ralph H. Johnson VA Medical Center	Completed	No outcome recorded
Phase 4	NCT00061802	Jun 2003 → Feb 2004	schizoaffective disorder, schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00048802	Aug 2002 → Aug 2006	bipolar disorder	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00043849	Jul 2002 → Jun 2005	Parkinson disease, dementia	National Institute on Aging (NIA)	Completed	No outcome recorded
Phase 4	NCT00254241	May 2002 → Jun 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00034905	Jul 2001 → Sep 2002	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00182013	Jun 2001 → Feb 2004	bipolar disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00014001	Dec 2000 → Dec 2004	schizophrenia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00018668	Oct 2000 → Sep 2004	schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 4	NCT00237861	? → Dec 2002	schizophrenia	Yale University	Completed	No outcome recorded
Phase 4	NCT00295412	—	schizophrenia, substance-related disorder	University of Montreal	Completed	No outcome recorded

Phase not applicable26 trials
—	NCT04728581	Jan 2024 → May 2026 overdue	insomnia, osteoarthritis, knee	St. Anna Ziekenhuis, Geldrop, Netherlands	Not yet recruiting	No outcome recorded
—	NCT05480150	Nov 2021 → Dec 2026 expected	bipolar disorder, major depressive disorder	First Affiliated Hospital of Zhejiang University	Recruiting	No outcome recorded
—	NCT05098353	Apr → Nov 2021	bipolar disorder	Federal Stare Budgetary Scientific Institution, Mental Health Research Center	Unknown	No outcome recorded
—	NCT06200584	Jan → Jun 2021	poisoning	Dr Rabia Arshad	Completed	No outcome recorded
—	NCT04209166	Aug 2019 → Oct 2022	major depressive disorder	Shanghai Mental Health Center	Unknown	No outcome recorded
—	NCT02451306	Jun 2015 → May 2017	bipolar disorder, depressive disorder	RWTH Aachen University	Unknown	No outcome recorded
—	NCT03019887	Apr 2011 → Jan 2017	schizophrenia	Juntendo University	Completed	No outcome recorded
—	NCT01066143	Feb 2010 → Feb 2013	generalized anxiety disorder	Mclean Hospital	Terminated	No outcome recorded
—	NCT01066156	Feb 2010 → Mar 2015	post-traumatic stress disorder	Cambridge Health Alliance	Completed	No outcome recorded
—	NCT01971203	Sep 2009 → Jun 2013	generalized anxiety disorder, major depressive disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
—	NCT00688818	Jun 2008 → Jun 2013	dysthymic disorder, generalized anxiety disorder, major depressive disorder, panic disorder +2	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT01527448	Apr 2008 → Jul 2010	postpartum depression	BC Women's Hospital & Health Centre	Completed	No outcome recorded
—	NCT00642369	Mar 2008 → Jul 2009	schizophrenia	Guang Dong Provincial Mental Health Institute	Completed	No outcome recorded
—	NCT00742638	Mar 2008 → May 2010	bipolar disorder	Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
—	NCT00617396	Feb 2008 → Jan 2012	bowel dysfunction	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT00631748	Feb 2008 → Jul 2010	cocaine abuse, cocaine dependence	Seattle Institute for Biomedical and Clinical Research	Completed	No outcome recorded
—	NCT00631722	May 2007 → Jan 2008	schizophrenia	Peking University	Completed	No outcome recorded
—	NCT00328822	Dec 2006 → Aug 2007	insomnia	Khon Kaen University	Completed	No outcome recorded
—	NCT00493233	Nov 2006 → Dec 2008	schizophrenia	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT00518973	Jul 2006 → May 2010	anorexia nervosa	University of California, San Diego	Completed	No outcome recorded
—	NCT00232570	Nov 2005 → Dec 2009	Alzheimer disease, insomnia	University of Vermont	Unknown	No outcome recorded
—	NCT00207064	Apr 2004 → Sep 2008	schizophrenia	Birte Glenthoj	Completed	No outcome recorded
—	NCT00231101	Jan 2004 → Jun 2006	—	Arthur P. Noyes Research Foundation	Unknown	No outcome recorded
—	NCT00222495	Aug 2002 → Aug 2006	schizoaffective disorder, schizophrenia, schizophreniform disorder	University of Minnesota	Completed	No outcome recorded
—	NCT00015548	Mar 2001 → Oct 2004	Alzheimer disease	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00018642	Apr 1997 → Mar 2002	schizoaffective disorder, schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded

Also used as a comparator or background therapy in 118 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06546358 Comparator	Sep 2024 → Sep 2025 overdue	postpartum depression	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Not yet recruiting	No outcome recorded
Phase 17 trials
Phase 1	NCT05542264 Comparator	Nov 2022 → Feb 2024	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT05402111 Comparator	Jun 2022 → Sep 2023	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT04310579 Comparator	Jun 2020 → May 2021	respiratory underresponsiveness to hypoxia and hypercapnia	Food and Drug Administration (FDA)	Completed	No outcome recorded
Phase 1	NCT03565068 Background	Jun 2018 → Apr 2020	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT02181803 Background	Aug 2014 → Apr 2015	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01400165 Comparator	Jul → Dec 2011	—	University of Ottawa	Unknown	No outcome recorded
Phase 1	NCT00832221 Comparator	Jan → Sep 2009	depressive disorder	AstraZeneca	Completed	No outcome recorded

Phase 212 trials
Phase 2	NCT07654348 Comparator	Jul 2026 → Jul 2029 expected	bipolar II disorder	First Affiliated Hospital of Zhejiang University	Not yet recruiting	No outcome recorded
Phase 2	NCT04521478 Comparator	Nov 2020 → Jan 2024	major depressive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT04164758 Comparator	Oct 2019 → Sep 2020	Parkinson disease	ACADIA Pharmaceuticals Inc.	Terminated	No outcome recorded
Phase 2	NCT03557931 Background	Jul 2018 → Oct 2019	schizophrenia	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 2	NCT03319953 Background	Dec 2017 → Sep 2019	schizophrenia	Neurocrine Biosciences	Completed	No outcome recorded
Phase 2	NCT03321526 Comparator	Dec 2017 → Jun 2019	major depressive disorder	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT01323205 Background	May 2011 → Nov 2012	schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT01052103 Background	Jan 2010 → Jun 2012	schizophrenia	Denovo Biopharma LLC	Completed	No outcome recorded
Phase 2	NCT00893841 Comparator	Feb 2009 → Jan 2013	bipolar depression	Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.	Completed	No outcome recorded
Phase 2	NCT00771134 Comparator	Dec 2008 → Jun 2009	bipolar disorder	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 2	NCT00561587 Comparator	Nov 2007 → Aug 2009	alcohol abuse, alcohol dependence	Institute of Application-oriented Research and Clinical Trials GmbH	Completed	No outcome recorded
Phase 2	NCT00509067 Background	Nov 2007 → Mar 2011	schizophrenia	Georgetown University	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT01129674 Comparator	Jun 2010 → Oct 2012	schizophrenia	Eli Lilly and Company	Terminated	No outcome recorded
Phase 2/3	NCT00462618 Comparator	Apr 2007 → Mar 2008	insomnia	Michael E. DeBakey VA Medical Center	Completed	No outcome recorded
Phase 328 trials
Phase 3	NCT04513912 Comparator	Sep 2020 → Oct 2023	major depressive disorder	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT04338321 Comparator	Aug 2020 → Jan 2022	major depressive disorder	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT04115319 Comparator	Nov 2019 → Dec 2022	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 3	NCT03465787 Comparator	Apr 2018 → Oct 2022	schizophrenia	Bukwang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT02720198 Comparator	Jan 2017 → Jun 2018	major depressive disorder	Duke University	Completed	No outcome recorded
Phase 3	NCT02431702 Comparator	Jul 2015 → Nov 2019	schizophrenia	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT02297763 Comparator	Mar 2015 → Sep 2016	delirium	Seoul National University Hospital	Unknown	No outcome recorded
Phase 3	NCT01727726 Comparator	Dec 2012 → Oct 2016	major depressive disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 3	NCT01363310 Comparator	Oct 2010 → Jan 2013	major depressive disorder	Physicians Research And Education Network	Terminated	No outcome recorded
Phase 3	NCT01081769 Comparator	Feb 2010 → Feb 2013	schizophrenia	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00857818 Comparator	Apr 2009 → Mar 2010	bipolar I disorder, metabolic syndrome X, schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Terminated	No outcome recorded
Phase 3	NCT00789698 Comparator	Dec 2008 → Jul 2011	schizophrenia	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00789854 Comparator	Nov 2008 → Aug 2009	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00773162 Comparator	Oct 2008 → Aug 2013	social phobia	START Clinic for Mood and Anxiety Disorders	Completed	No outcome recorded
Phase 3	NCT00790192 Comparator	Oct 2008 → Jul 2010	schizophrenia	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00880919 Comparator	Jun 2008 → Mar 2013	borderline personality disorder	University of Minnesota	Completed	No outcome recorded
Phase 3	NCT00704509 Comparator	Jun 2008 → Aug 2009	schizophrenia	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 3	NCT00654706 Comparator	Mar 2008 → Jan 2010	schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded
Phase 3	NCT00658645 Comparator	Mar 2008 → Aug 2009	schizophrenia	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 3	NCT00517387 Comparator	Sep 2007 → Sep 2010	major depressive disorder	University of British Columbia	Completed	No outcome recorded
Phase 3	NCT00396214 Comparator	Apr 2007 → Jan 2008	schizophrenia	Solvay Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00315900 Comparator	May 2006 → Dec 2007	dementia	Tuscaloosa Research & Education Advancement Corporation	Terminated	No outcome recorded
Phase 3	NCT00309699 Comparator	Apr 2006 → Sep 2007	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00183443 Comparator	Feb 2005 → Nov 2010	bipolar disorder, schizophrenia	Palo Alto Veterans Institute for Research	Completed	No outcome recorded
Phase 3	NCT00149734 Background	Jan 2005 → May 2010	schizophrenia	University of Colorado, Denver	Completed	No outcome recorded
Phase 3	NCT00216476 Comparator	Oct 2004 → Nov 2007	schizophrenia	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00237913 Comparator	Jul 2004 → Aug 2005	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 3	NCT00177164 Comparator	Nov 2003 → Mar 2008	bipolar I disorder	University of Pittsburgh	Completed	No outcome recorded

Phase 458 trials
Phase 4	NCT05085808 Comparator	Mar 2028 → Jul 2029	delirium	University of Southern California	Withdrawn	No outcome recorded
Phase 4	NCT05741502 Comparator	Aug 2023 → Jan 2026	schizophrenia	Ohio State University	Terminated	No outcome recorded
Phase 4	NCT04513314 Comparator	Mar 2023	COVID-19, delirium, viral pneumonia	University of Miami	Withdrawn	No outcome recorded
Phase 4	NCT04373317 Comparator	Oct 2022 → Oct 2026 expected	Parkinson disease	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT05590637 Comparator	Apr 2022 → Aug 2026 overdue	Lewy body dementia, Parkinson disease	The University of Texas Health Science Center at San Antonio	Recruiting	No outcome recorded
Phase 4	NCT04936126 Comparator	Aug 2021 → Jul 2024	—	All India Institute of Medical Sciences, Bhubaneswar	Unknown	No outcome recorded
Phase 4	NCT04898270 Background	Dec 2019 → Dec 2020	metabolic syndrome X, schizophrenia	Taichung Veterans General Hospital	Completed	No outcome recorded
Phase 4	NCT03568500 Background	May 2018 → May 2019	schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 4	NCT02562287 Comparator	Oct 2015 → Jun 2019	bipolar disorder	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 4	NCT02282085 Comparator	Dec 2014 → Dec 2017	schizophrenia	Matt Byerly	Unknown	No outcome recorded
Phase 4	NCT02237417 Comparator	Sep 2014 → Nov 2018	schizophrenia	University of Utah	Completed	No outcome recorded
Phase 4	NCT02040883 Background	Feb → Dec 2014	schizophrenia	Qingyun Yin	Unknown	No outcome recorded
Phase 4	NCT02612948 Comparator	Nov 2013 → Jun 2014	drug-induced akathisia	University of Tennessee Graduate School of Medicine	Completed	No outcome recorded
Phase 4	NCT01844700 Comparator	Jul 2013 → Apr 2014	obesity due to melanocortin 4 receptor deficiency	Northwell Health	Terminated	No outcome recorded
Phase 4	NCT01833897 Background	Mar 2013 → Jul 2014	bipolar disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT01662297 Comparator	Jul 2012 → Oct 2015	insomnia, mental disorder, substance-related disorder	VA Connecticut Healthcare System	Terminated	No outcome recorded
Phase 4	NCT01526148 Comparator	Jan 2012 → Jan 2015	bipolar disorder	University Hospitals Cleveland Medical Center	Terminated	No outcome recorded
Phase 4	NCT01588457 Comparator	Jun 2011 → Dec 2016	bipolar I disorder, bipolar II disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 4	NCT01213836 Comparator	Nov 2010 → Aug 2011	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01587066 Comparator	Aug 2010 → Aug 2011	bipolar depression	Bo-Hyun Yoon	Withdrawn	No outcome recorded
Phase 4	NCT01193166 Comparator	Aug 2010 → Sep 2012	schizophrenia	Ortho-McNeil Janssen Scientific Affairs, LLC	Withdrawn	No outcome recorded
Phase 4	NCT01157351 Comparator	May 2010 → Dec 2013	schizophrenia	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 4	NCT01047215 Comparator	Aug 2009	bipolar disorder, schizophrenia	Taichung Veterans General Hospital	Unknown	No outcome recorded
Phase 4	NCT01305707 Comparator	Jul 2009 → Jul 2014	major depressive disorder	Hospital Universitari de Bellvitge	Terminated	No outcome recorded
Phase 4	NCT01043679 Comparator	Jul 2009 → Jun 2010	manic bipolar affective disorder	Taichung Veterans General Hospital	Unknown	No outcome recorded
Phase 4	NCT00926393 Comparator	Jun → Aug 2009	bipolar depression	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00931723 Comparator	Jun 2009 → Nov 2010	manic bipolar affective disorder	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00912535 Comparator	May 2009 → Jul 2010	anxiety disorder, mood disorder	Chang Gung Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00806234 Comparator	Jan 2009 → Mar 2014	psychotic disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT02526030 Comparator	Oct 2008 → Feb 2014	schizophrenia	Fundación Marques de Valdecilla	Completed	No outcome recorded
Phase 4	NCT00681629 Background	Jul → Nov 2008	schizoaffective disorder, schizophrenia, schizophreniform disorder	AstraZeneca	Terminated	No outcome recorded
Phase 4	NCT00550394 Comparator	Apr 2008 → Jun 2010	alcohol abuse, bipolar disorder	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00554658 Comparator	Mar 2008 → Dec 2010	schizophrenia	University of Regensburg	Completed	No outcome recorded
Phase 4	NCT00619892 Comparator	Feb 2008 → Dec 2011	panic disorder	Indiana University	Completed	No outcome recorded
Phase 4	NCT01458964 Comparator	Jan 2008 → Dec 2013	fibromyalgia	East Tennessee State University	Completed	No outcome recorded
Phase 4	NCT00508157 Comparator	Nov 2007 → Mar 2009	metabolic syndrome X, schizophrenia	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 4	NCT00579280 Comparator	Jul 2007 → Dec 2010	bipolar disorder, generalized anxiety disorder, panic disorder	University of South Florida	Completed	No outcome recorded
Phase 4	NCT01195363 Comparator	Apr 2007 → Dec 2010	bipolar disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 4	NCT00457197 Comparator	Mar 2007 → Jul 2011	alcohol dependence, bipolar disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00423878 Comparator	Jan 2007 → Oct 2009	schizoaffective disorder, schizophrenia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00397020 Comparator	Dec 2006 → Dec 2008	bipolar disorder	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT00393978 Comparator	Nov 2006 → Dec 2011	bipolar disorder, cannabis dependence	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00375557 Comparator	Oct 2006 → Sep 2007	Alzheimer disease	University of Cincinnati	Withdrawn	No outcome recorded
Phase 4	NCT00325689 Comparator	Jul 2006 → Oct 2007	schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 4	NCT00330863 Comparator	May 2006 → Jan 2011	schizoaffective disorder, schizophrenia	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00457366 Comparator	May 2006 → Aug 2008	—	University of Southern California	Completed	No outcome recorded
Phase 4	NCT01224067 Comparator	Mar 2006 → Jul 2008	social phobia	Cambridge Health Alliance	Completed	No outcome recorded
Phase 4	NCT00352469 Comparator	Feb 2006 → Nov 2008	alcohol dependence, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder +1	Creighton University	Completed	No outcome recorded
Phase 4	NCT00256997 Comparator	Jan 2006 → Apr 2009	schizophrenia	Janssen-Ortho Inc., Canada	Terminated	No outcome recorded
Phase 4	NCT00223210 Comparator	Nov 2005 → Dec 2007	bipolar disorder, cocaine dependence	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT02534363 Comparator	Oct 2005 → Jan 2011	schizophrenia	Fundación Marques de Valdecilla	Completed	No outcome recorded
Phase 4	NCT02305823 Comparator	Oct 2005 → Feb 2011	schizophrenia	Fundación Marques de Valdecilla	Completed	No outcome recorded
Phase 4	NCT00654576 Comparator	Feb 2005 → Dec 2007	schizophrenia	Central South University	Completed	No outcome recorded
Phase 4	NCT00246259 Comparator	Oct 2004 → Dec 2008	schizoaffective disorder, schizophrenia, schizophreniform disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 4	NCT00304616 Background	Oct 2004 → Jun 2006	schizophrenia	Korea Otsuka Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT00932529 Comparator	Feb 2003 → Jan 2010	psychotic disorder	University of Bergen	Completed	No outcome recorded
Phase 4	NCT00223249 Comparator	Nov 2002 → Aug 2004	alcohol-related disorders, bipolar disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00044655 Comparator	Jul 2001 → Mar 2009	schizophrenia	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded

Phase not applicable10 trials
—	NCT06581302 Comparator	Sep 2024 → Dec 2025 overdue	psychotic disorder	Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
—	NCT06467474 Background	Mar 2024 → Jun 2025 overdue	major depressive disorder	Ricardo Alberto Moreno, M.D., Ph.D.	Recruiting	No outcome recorded
—	NCT05801289 Comparator	Dec 2022 → Apr 2023	delirium	Ain Shams University	Unknown	No outcome recorded
—	NCT02192723 Comparator	Jun 2012 → Jun 2014	schizophrenia	Beijing HuiLongGuan Hospital	Completed	No outcome recorded
—	NCT02137616 Comparator	Jun 2012 → Dec 2014	psychotic disorder	Central South University	Unknown	No outcome recorded
—	NCT00893581 Comparator	Mar 2009 → Feb 2016	manic bipolar affective disorder	University of Cincinnati	Completed	No outcome recorded
—	NCT01552837 Comparator	Dec 2007 → Feb 2010	bipolar disorder	RWTH Aachen University	Completed	No outcome recorded
—	NCT00280501 Comparator	Aug 2005 → Aug 2006	—	Medical University of Vienna	Completed	No outcome recorded
—	NCT00227123 Comparator	Oct 2002 → Nov 2006	bipolar disorder, cocaine dependence, methamphetamine dependence	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT00515723 Comparator	Sep 2001 → Dec 2008	hyperglycemia, schizoaffective disorder, schizophrenia, type 2 diabetes mellitus	Washington University School of Medicine	Completed	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2012-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Generic Seroquel® in the United States tevapharm.com ↗
2009-09-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update on Generic Seroquel® Litigation tevapharm.com ↗
2008-12-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Generic Seroquel® Tablets tevapharm.com ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 382 sources stand behind the page.

Field	Value	Cited text
Known as	quetiapine	“Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗ 335 “This study attempts to observe the efficacy (response time) and safety of the second-generation antipsychotic agent-quetiapine versus the first-generation antipsychotic...” NCT00631722 ↗ “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation...” NCT01903200 ↗ “Subjects (N = 44) who failed to respond to SSRIs were randomly assigned to 1 of 3 atypical antipsychotics -- olanzapine, quetiapine, or risperidone -- and were consecutively...” PMID 19422759 ↗ May 2009 “The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation...” NCT01871974 ↗ “All the eligible participants will be randomly assigned to an oral atypical antipsychotic (risperidone, olanzapine, quetiapine, and where commercially available, aripiprazole...” NCT00256997 ↗ “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone,...” NCT02181803 ↗ “A study to evaluate the effect of food on the plasma concentration changes of quetiapine after oral administration of FK949E (extended release formulation of quetiapine) in...” NCT01871987 ↗ “Quetiapine is an atypical antipsychotic with a favorable side effect profile, and may be a promising medication for the treatment of alcohol dependence, particularly Type B alcoholism.” PMID 17632217 ↗ Aug 2007 “Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.” NCT00246259 ↗ “This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety.” NCT00352469 ↗ “The objective of the study was to assess the effect of multiple-dose fluvoxamine on the pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects.” NCT01908296 ↗ “United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)” NCT01052103 ↗ “Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.” NCT03319953 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.” NCT00149734 ↗ “Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) in a 6-week, double-blind, randomized study.” PMID 17592906 ↗ Jun 2007 “Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder” NCT00177164 ↗ “Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder” NCT03872596 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression.” NCT01833897 ↗ “A dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is quetiapine.” NCT05690698 ↗ “Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine.” NCT04898270 ↗ “Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate” NCT00206128 ↗ “In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on.” NCT06467474 ↗ “AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone” NCT03565068 ↗ “Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day” NCT01971203 ↗ “once-daily extended release quetiapine fumarate (quetiapine XR).” PMID 18021496 ↗ Jan 2008 “Quetiapine (according to response, and tolerance)25-500mg” NCT01000402 ↗ “- Quetiapine 50-600 mg/d. N05AH04” NCT01305707 ↗ “quetiapine fumarate (Seroquel®)” NCT02237417 ↗ “Quetiapine group:” NCT01357967 ↗ NCT00081380 ↗ NCT00879307 ↗ NCT00254735 ↗ NCT00883493 ↗ NCT00254748 ↗ NCT00254774 ↗ NCT00085891 ↗ NCT00422214 ↗ NCT00982345 ↗ NCT00375557 ↗ NCT00857584 ↗ NCT01858948 ↗ NCT00817648 ↗ NCT00043849 ↗ NCT02142556 ↗ NCT00159770 ↗ NCT00771134 ↗ NCT01133821 ↗ NCT00790192 ↗ NCT02534363 ↗ NCT00554658 ↗ NCT00954603 ↗ NCT01697709 ↗ NCT00811473 ↗ NCT00237861 ↗ NCT03465787 ↗ NCT05402111 ↗ NCT00954122 ↗ NCT00457366 ↗ NCT00422123 ↗ NCT04280965 ↗ NCT00322595 ↗ NCT00237913 ↗ NCT00457197 ↗ NCT01213836 ↗ NCT02650102 ↗ NCT00882518 ↗ NCT00280501 ↗ NCT00621647 ↗ NCT00237393 ↗ NCT01071135 ↗ NCT00951483 ↗ NCT00619892 ↗ NCT00113295 ↗ NCT00550147 ↗ NCT01725282 ↗ NCT02901587 ↗ NCT00617396 ↗ NCT00231101 ↗ NCT00297947 ↗ NCT02192723 ↗ NCT03572257 ↗ NCT05973786 ↗ NCT01458964 ↗ NCT06581302 ↗ NCT00832221 ↗ NCT00206102 ↗ NCT00393978 ↗ NCT01587066 ↗ NCT04728581 ↗ NCT00550394 ↗ NCT00521365 ↗ NCT01871701 ↗ NCT00254813 ↗ NCT01607762 ↗ NCT00278941 ↗ NCT06200584 ↗ NCT00014001 ↗ NCT07654348 ↗ NCT00579280 ↗ NCT01213121 ↗ NCT00216476 ↗ NCT01938859 ↗ NCT00742638 ↗ NCT01250847 ↗ NCT00314184 ↗ NCT00314210 ↗ NCT00114686 ↗ NCT00534599 ↗ NCT00498628 ↗ NCT04338321 ↗ NCT00229645 ↗ NCT00508157 ↗ NCT00321490 ↗ NCT00498004 ↗ NCT04446234 ↗ NCT00090324 ↗ NCT00044655 ↗ NCT00912535 ↗ NCT00208143 ↗ NCT01331304 ↗ NCT00564564 ↗ NCT04950868 ↗ NCT00462618 ↗ NCT00388973 ↗ NCT00766350 ↗ NCT00838032 ↗ NCT03739476 ↗ NCT01526148 ↗ NCT00254787 ↗ NCT00334035 ↗ NCT00090311 ↗ NCT01047215 ↗ NCT01200901 ↗ NCT00806234 ↗ NCT02040883 ↗ NCT00334126 ↗ NCT05480150 ↗ NCT02051387 ↗ NCT01164059 ↗ NCT00631748 ↗ NCT01224067 ↗ NCT00305422 ↗ NCT00389064 ↗ NCT01244711 ↗ NCT02137616 ↗ NCT00221468 ↗ NCT00509067 ↗ NCT03568500 ↗ NCT00119652 ↗ NCT00789854 ↗ NCT01363310 ↗ NCT00320268 ↗ NCT00015548 ↗ NCT00983320 ↗ NCT01193166 ↗ NCT03019887 ↗ NCT02451306 ↗ NCT00893841 ↗ NCT02056171 ↗ NCT04373317 ↗ NCT06062953 ↗ NCT00567866 ↗ NCT00034905 ↗ NCT00660595 ↗ NCT00228462 ↗ NCT02282085 ↗ NCT01662297 ↗ NCT03557931 ↗ NCT00688818 ↗ NCT07152184 ↗ NCT00671853 ↗ NCT00222495 ↗ NCT06433635 ↗ NCT01672554 ↗ NCT00515723 ↗ NCT00277667 ↗ NCT01129674 ↗ NCT00232336 ↗ NCT00174603 ↗ NCT05085808 ↗ NCT00428350 ↗ NCT00872716 ↗ NCT02131545 ↗ NCT00255515 ↗ NCT00932529 ↗ NCT00919607 ↗ NCT00207064 ↗ NCT00681668 ↗ NCT00448578 ↗ NCT00681629 ↗ NCT00330863 ↗ NCT00223210 ↗ NCT00223249 ↗ NCT05303935 ↗ NCT00704509 ↗ NCT04513314 ↗ NCT05801289 ↗ NCT00668265 ↗ NCT00397020 ↗ NCT00926393 ↗ NCT05793632 ↗ NCT00232414 ↗ NCT02562287 ↗ NCT00642369 ↗ NCT00518973 ↗ NCT05240261 ↗ NCT02462473 ↗ NCT00640562 ↗ NCT00253266 ↗ NCT00370500 ↗ NCT00347425 ↗ NCT00868374 ↗ NCT04209166 ↗ NCT02374567 ↗ NCT06546358 ↗ NCT00309699 ↗ NCT05603104 ↗ NCT00182442 ↗ NCT00434876 ↗ NCT00407199 ↗ NCT00061802 ↗ NCT00215254 ↗ NCT00087750 ↗ NCT02297763 ↗ NCT00232570 ↗ NCT00837343 ↗ NCT00302770 ↗ NCT00295412 ↗ NCT02087579 ↗ NCT00486798 ↗ NCT00751504 ↗ NCT02087631 ↗ NCT01811459 ↗ NCT00640601 ↗ NCT00351169 ↗ NCT01527448 ↗ NCT00318539 ↗ NCT02845453 ↗ NCT01893229 ↗ NCT00328822 ↗ NCT00107731 ↗ NCT05098353 ↗ NCT00156715 ↗ NCT00654576 ↗ NCT04310579 ↗ NCT00060489 ↗ NCT00654706 ↗ NCT00048802 ↗ NCT00255879 ↗ NCT01128114 ↗ NCT00606541 ↗ NCT01256177 ↗ NCT05590637 ↗ NCT00893581 ↗ NCT00018668 ↗ NCT02305823 ↗ NCT00018642 ↗ NCT00892463 ↗ NCT00161018 ↗ NCT04513912 ↗ NCT00423878 ↗ NCT03321526 ↗ NCT00782405 ↗ NCT03004521 ↗ NCT02526030 ↗ NCT00880919 ↗ NCT00986167 ↗ NCT00955474 ↗ NCT00090012 ↗ NCT00743366 ↗ NCT00658645 ↗ NCT00304473 ↗ NCT00396214 ↗ NCT00292370 ↗ NCT01119014 ↗ NCT00449397 ↗ NCT00517387 ↗ NCT02431702 ↗ NCT00186043 ↗ NCT00208819 ↗ NCT00953108 ↗ NCT03207438 ↗ NCT00723970 ↗ NCT00789698 ↗ NCT01810380 ↗ NCT00182013 ↗ NCT00954681 ↗ NCT00779506 ↗ NCT04164758 ↗ NCT00325689 ↗ NCT00351910 ↗ NCT01400165 ↗ NCT00797927 ↗ NCT00457899 ↗ NCT00746421 ↗ NCT01157351 ↗ NCT00206141 ↗ NCT00139074 ↗ NCT00214578 ↗ NCT00329446 ↗ NCT00852631 ↗ NCT00252226 ↗ NCT05542264 ↗ NCT00122070 ↗ NCT00083954 ↗ NCT06333990 ↗ NCT00227123 ↗ NCT00329264 ↗ NCT00675896 ↗ NCT00326105 ↗ NCT00328978 ↗ NCT00584688 ↗ NCT04521478 ↗ NCT01844700 ↗ NCT00183443 ↗ NCT00857818 ↗ NCT00227305 ↗ NCT02307396 ↗ NCT04936126 ↗ NCT04115319 ↗ NCT01189318 ↗ NCT02612948 ↗ NCT00326144 ↗ NCT02720198 ↗ NCT00733668 ↗ NCT00181883 ↗ NCT01588457 ↗ NCT01197846 ↗ NCT01195363 ↗ NCT00466609 ↗ NCT00097032 ↗
Known as	extended-release formulation of quetiapine	“extended-release formulation of quetiapine” NCT01924520 ↗
Known as	FK949E	“The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation...” NCT01903200 ↗ 8 “The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation...” NCT01871974 ↗ “The objective of the study was to assess the effect of multiple-dose fluvoxamine on the pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects.” NCT01908296 ↗ NCT02362412 ↗ NCT01871987 ↗ NCT01725308 ↗ NCT01919008 ↗ NCT01924520 ↗ NCT01737268 ↗
Known as	QUET	“3. 320 begin double-blind treatment with quetiapine (QUET)” NCT00014001 ↗
Known as	Quetiapine (generic name): Seroquel (brand name)	“Quetiapine (generic name): Seroquel (brand name)” NCT00955474 ↗
Known as	Quetiapine 100 mg (Seroquel, Tablet)	“Quetiapine 100 mg (Seroquel, Tablet)” NCT01871701 ↗
Known as	quetiapine extended release	“The aim of this study was to compare the effect of quetiapine extended release (ER) versus aripiprazole on corrected QT interval (QTc) and QT dispersion (QTd) in youths with...” PMID 29185022 ↗ Nov 2017
Known as	Quetiapine extended-release (Seroquel XR)	“Quetiapine extended-release (Seroquel XR)” NCT00723970 ↗
Known as	quetiapine fumarate	“The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in...” NCT00811473 ↗ 50 “This pilot study evaluated the feasibility of extended-release quetiapine fumarate (quetiapine XR) for the treatment of patients with either a primary anxiety disorder or a...” PMID 23020711 ↗ Sep 2012 “This study investigated the efficacy and tolerability of adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with GAD and an inadequate response to...” PMID 24660224 ↗ Feb 2014 “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate...” NCT00329446 ↗ “This study evaluated once-daily extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with major depressive disorder (MDD) with inadequate...” PMID 20175941 ↗ Feb 2010 “The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.” NCT00227305 ↗ “BACKGROUND: Evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) once-daily monotherapy for patients with major depressive disorder (MDD).” PMID 20691481 ↗ Aug 2010 “This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety.” NCT00352469 ↗ “This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine derivative, as a potential medication for treating alcohol dependence.” NCT00498628 ↗ “This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD).” PMID 21694613 ↗ Aug 2011 “Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers” NCT00832221 ↗ “Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated)” NCT00090324 ↗ “extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms” PMID 25356632 ↗ Jan 2015 “Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD).” PMID 19668121 ↗ Jun 2009 “Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder” NCT00448578 ↗ “sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.” NCT00422214 ↗ “Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder” NCT00321490 ↗ “once-daily extended-release quetiapine fumarate (quetiapine XR; 300 mg/day) as add-on to ongoing antidepressant” PMID 23810357 ↗ Jun 2013 “treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo” NCT00388973 ↗ “Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression” NCT00083954 ↗ “Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia” NCT00234377 ↗ “Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.” NCT00124059 ↗ “Investigational product: quetiapine fumarate tablet 25 mg and 200 mg” NCT00742638 ↗ “Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)” NCT00206141 ↗ “Seroquel®, quetiapine fumarate (atypical antipsychotic)” NCT00081380 ↗ “Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)” NCT00882518 ↗ “Quetiapine Fumarate (SEROQUEL) Extended Release” NCT01256177 ↗ “SEROQUEL (quetiapine fumarate) Tablets” NCT00060489 ↗ “quetiapine fumarate tablet (Seroquel)” NCT00837343 ↗ “extended release quetiapine fumarate” PMID 23070803 ↗ Oct 2012 “Quetiapine fumarate (Seroquel XR)” NCT01128114 ↗ “Seroquel IR - quetiapine fumarate” NCT01213836 ↗ “Quetiapine fumarate (Seroquel) SR” NCT00422123 ↗ “quetiapine fumarate (Seroquel®)” NCT02237417 ↗ “Quetiapine Fumarate (SEROQUEL®)” NCT00114686 ↗ “Quetiapine Fumarate (Seroquel®)” NCT00229645 ↗ “quetiapine fumarate (SEROQUEL)” NCT00090311 ↗ “Quetiapine Fumarate (Seroquel)” NCT00428350 ↗ “Quetiapine fumarate (Seroquel)” NCT00852631 ↗ “quetiapine fumarate (Seroquel)” NCT00119652 ↗ “Quetiapine Fumarate (SEROQUEL)” NCT00621647 ↗ “Quetiapine fumarate (Seroquel)” NCT00733668 ↗ “Drug: Quetiapine fumarate” NCT00370500 ↗ “Drug: Quetiapine Fumarate” NCT00122070 ↗ “Drug: Quetiapine fumarate” NCT00139074 ↗ “Drug: Quetiapine Fumarate” NCT04280965 ↗ NCT01254721 ↗ NCT00672490 ↗ NCT00306540 ↗ NCT00622245 ↗ NCT00702676 ↗
Known as	Quetiapine Fumarate Extended-Release	“A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in...” NCT00640601 ↗ 1 “Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study.” PMID 24504819 ↗ Feb 2014
Known as	Quetiapine Fumarate Sustained Release	“Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day.” NCT00675896 ↗
Known as	Quetiapine fumarate XR	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00931723 ↗
Known as	Quetiapine SR	“A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients” NCT00619892 ↗ 1 “Quetiapine SR (Quetiapine Sustained Release)” NCT00579280 ↗
Known as	Quetiapine Sustained Release	“Quetiapine SR (Quetiapine Sustained Release)” NCT00579280 ↗
Known as	quetiapine XR	“The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in...” NCT00811473 ↗ 29 “This pilot study evaluated the feasibility of extended-release quetiapine fumarate (quetiapine XR) for the treatment of patients with either a primary anxiety disorder or a...” PMID 23020711 ↗ Sep 2012 “This study investigated the efficacy and tolerability of adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with GAD and an inadequate response to...” PMID 24660224 ↗ Feb 2014 “This study evaluated once-daily extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with major depressive disorder (MDD) with inadequate...” PMID 20175941 ↗ Feb 2010 “The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients...” PMID 26474010 ↗ Dec 2015 “All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day...” NCT00517387 ↗ “Effects of once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy on sleep quality and disturbance in patients with major depressive disorder (MDD) were evaluated.” PMID 23673347 ↗ May 2013 “This study is a pooled, post-hoc analysis evaluating once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD).” PMID 24394383 ↗ Sep 2014 “BACKGROUND: Evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) once-daily monotherapy for patients with major depressive disorder (MDD).” PMID 20691481 ↗ Aug 2010 “Quetiapine fumarate extended-release (quetiapine XR) has demonstrated efficacy in the treatment of MDD and has been shown to have analgesic properties in patients with depression.” PMID 24504819 ↗ Feb 2014 “Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.” NCT00389064 ↗ “This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD).” PMID 21694613 ↗ Aug 2011 “extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms” PMID 25356632 ↗ Jan 2015 “Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) in a 6-week, double-blind, randomized study.” PMID 17592906 ↗ Jun 2007 “Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD).” PMID 19668121 ↗ Jun 2009 “once-daily extended-release quetiapine fumarate (quetiapine XR; 300 mg/day) as add-on to ongoing antidepressant” PMID 23810357 ↗ Jun 2013 “Quetiapine XR is the first approved drug in China for the treatment of bipolar disorder.” PMID 26911380 ↗ Feb 2016 “Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg.” NCT01071135 ↗ “once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy” PMID 22054797 ↗ Nov 2011 “Treatment with quetiapine XR will last for 4 weeks or until day 28.” NCT02087631 ↗ “quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule” NCT04115319 ↗ “The endpoint quetiapine XR mean daily dose ± SD was 150 ± 106 mg.” PMID 26379759 ↗ Sep 2015 “once-daily extended release quetiapine fumarate (quetiapine XR).” PMID 18021496 ↗ Jan 2008 “extended-release quetiapine fumarate (quetiapine XR)” PMID 24816198 ↗ May 2014 “Extended release quetiapine (quetiapine XR)” NCT00857584 ↗ “Quetiapine XR 2 300 mg tablets, QD” NCT03465787 ↗ “100 mg single-dose Quetiapine XR” NCT00872716 ↗ “Quetiapine XR (Seroquel XR)” NCT00954122 ↗ “Drug: Quetiapine XR” NCT00606541 ↗ NCT00600756 ↗
Known as	Seroquel	“The effect of quetiapine alone or adjunctive with mood stabilizers in the treatment of acute mania in patients with bipolar disorder has been confirmed through 4 phase III...” NCT00742638 ↗ 59 “Participants who continue to have anxiety symptoms will enter the 8-week Phase II, in which they continue taking Paxil CR and they will also be randomly assigned (by chance,...” NCT00113295 ↗ “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate...” NCT00329446 ↗ “The medication quetiapine also known as seroquel works by activating certain systems in the brain, such as ones known as dopamine and serotonin chemical systems in the brain.” NCT00584688 ↗ “Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel).” NCT01133821 ↗ “Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone” NCT00208143 ↗ “whether Quetiapine (Seroquel) is significantly more effective than Olanzapine (Zyprexa) in improving neurocognitive deficits, community functioning and quality of life” NCT00182442 ↗ “The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.” NCT00156715 ↗ “The primary aim of this study is to determine the safety and efficacy of quetiapine (Seroquel) for the treatment of psychosis and/or agitation” NCT00043849 ↗ “Quetiapine (marketed under the brand name Seroquel) has been approved by the FDA since 1997 to help adults who suffer from schizophrenia” NCT00393978 ↗ “Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers” NCT00832221 ↗ “Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated)” NCT00090324 ↗ “Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder” NCT00448578 ↗ “sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.” NCT00422214 ↗ “Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder” NCT00321490 ↗ “Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose” NCT00280501 ↗ “Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder” NCT00329264 ↗ “A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD” NCT00237393 ↗ “Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder” NCT00320268 ↗ “Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression” NCT00083954 ↗ “Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate” NCT00206128 ↗ “Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify)” NCT00177164 ↗ “Quetiapine (Seroquel ®), an atypical antipsychotic registered for use in schizophrenia” NCT00318539 ↗ “Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day” NCT00328978 ↗ “intravenous cocaine and quetiapine (seroquel) in cocaine-experienced subjects” NCT00087750 ↗ “Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.” NCT00124059 ↗ “olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel)” NCT00048802 ↗ “Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)” NCT00206141 ↗ “Seroquel®, quetiapine fumarate (atypical antipsychotic)” NCT00081380 ↗ “Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)” NCT00882518 ↗ “Quetiapine Fumarate (SEROQUEL) Extended Release” NCT01256177 ↗ “quetiapine (Seroquel) sustained release (SR)” NCT00234377 ↗ “SEROQUEL (quetiapine fumarate) Tablets” NCT00060489 ↗ “quetiapine fumarate tablet (Seroquel)” NCT00837343 ↗ “Quetiapine fumarate (Seroquel) SR” NCT00422123 ↗ “quetiapine fumarate (Seroquel®)” NCT02237417 ↗ “Quetiapine Fumarate (SEROQUEL®)” NCT00114686 ↗ “Quetiapine Fumarate (Seroquel®)” NCT00229645 ↗ “Quetiapine Fumarate (Seroquel)” NCT00428350 ↗ “quetiapine fumarate (Seroquel)” NCT00119652 ↗ “Quetiapine fumarate (Seroquel)” NCT00852631 ↗ “Quetiapine fumarate (Seroquel)” NCT00733668 ↗ “quetiapine fumarate (SEROQUEL)” NCT00090311 ↗ “Drug: Quetiapine XR (seroquel)” NCT01527448 ↗ “quetiapine (Seroquel) XR” NCT00893841 ↗ “Seroquel (quetiapine)” NCT00228462 ↗ “Seroquel (quetiapine)” NCT00214578 ↗ “Quetiapine/Seroquel” NCT00186043 ↗ NCT01066156 ↗ NCT00561587 ↗ NCT00254241 ↗ NCT01552837 ↗ NCT00674765 ↗ NCT00493233 ↗ NCT00411463 ↗ NCT00304616 ↗ NCT00511277 ↗ NCT00315900 ↗ NCT01043679 ↗ NCT00773162 ↗
Known as	SEROQUEL IR	“Seroquel IR - quetiapine fumarate” NCT01213836 ↗ 1 “SEROQUEL IR (quetiapine)” NCT00832221 ↗
Known as	Seroquel Prolong	“Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg.” NCT01071135 ↗
Known as	Seroquel SR	“The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients...” NCT00107731 ↗ 9 “The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE...” NCT00329446 ↗ “The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety...” NCT00322595 ↗ “This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety.” NCT00352469 ↗ “Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression” NCT00422214 ↗ “Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day.” NCT00675896 ↗ “treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo” NCT00388973 ↗ “PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.” NCT00326105 ↗ “Quetiapine Fumarate Sustained Release (SEROQUEL SR™)” NCT00278941 ↗ “Quetiapine fumarate (Seroquel) SR” NCT00422123 ↗
Known as	Seroquel SRTM	“A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM)...” NCT00326105 ↗ 2 “Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono- Therapy in the Treatment of Adult Patients With Major Depressive Disorder” NCT00351169 ↗ “Quetiapine Fumarate Sustained Release (Seroquel SRTM)” NCT00351910 ↗
Known as	Seroquel XR	“The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients...” NCT00107731 ↗ 13 “The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep,...” NCT00278941 ↗ “The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in...” NCT00811473 ↗ “The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE...” NCT00329446 ↗ “Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers” NCT00832221 ↗ “PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.” NCT00326105 ↗ “Seroquel XR- quetiapine fumarate extended release” NCT01213836 ↗ “Extended-release Quetiapine (Seroquel XR)” NCT01971203 ↗ “Quetiapine(Seroquel-XR) 50~800mg a day” NCT01250847 ↗ “Quetiapine (Seroquel XR® 800 mg/day)” NCT02901587 ↗ “Quetiapine fumarate (Seroquel XR)” NCT01128114 ↗ “quetiapine (Seroquel XR)” NCT00982345 ↗ NCT01066143 ↗ NCT01727726 ↗
Known as	Seroquel_XR (Quetiapine Fumarate XR)	“Seroquel_XR (Quetiapine Fumarate XR)” NCT00882518 ↗
Known as	SeroquelXL	“This study is being carried out to see if extended release quetiapine fumarate (Seroquel®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) /...” NCT00534599 ↗
Action	Inhibit	“weak Dopamine2 (D2) receptor blocking ability” NCT00156715 ↗
Modality	Small molecule	“a dibenzothiazepine derivative” NCT00498628 ↗
Route	Oral	“oral variable dose” NCT00139074 ↗